Exp Neurobiol 2014; 23(2): 163-168
Published online June 30, 2014
© The Korean Society for Brain and Neural Sciences
Junsung Woo1,2, Suengmok Cho3 and C. Justin Lee1,2*
1Center for Neural Science and Functional Connectomics, Korea Institute of Science and Technology (KIST), Seoul 136-791, 2Neuroscience Program, University of Science and Technology (UST), Daejeon 305-350, 3Korea Food Research Institute, Seongnam 463-746, Korea
Isoliquiritigenin (ILTG) is a chalcone compound and shows various pharmacological properties, including antioxidant and anti-inflammatory activities. In recent study, we have reported a novel role of ILTG in sleep through a positive allosteric modulation of gamma-aminobutyric acid type A (GABAA)-benzodiazepine (BZD) receptors. However, the effect of ILTG in GABAAR-mediated synaptic response in brain has not been tested yet. Here we report that ILTG significantly prolonged the decay of spontaneous inhibitory postsynaptic currents (sIPSCs) mediated by GABAAR in mouse hippocampal CA1 pyramidal neurons without affecting amplitude and frequency of sIPSCs. This enhancement was fully inhibited by flumazenil (FLU), a specific GABAA-BZD receptor antagonist. These results suggest a potential role of ILTG as a modulator of GABAergic synaptic transmission.
Keywords: Isoliquiritigenin, GABAA-BZD receptor, sIPSC
Isoliquiritigenin (ILTG, 2',4',4'-trihydroxychalcone) is a chalcone compound and found in various flavonoids such as
In the present study, we investigated the modulation of GABAergic synaptic response by ILTG in mouse hippocampal CA1 pyramidal cell using whole-cell patch clamp technique. We found that ILTG specifically enhanced the decay tau of sIPSC by modulating GABAA-BZD receptor. However, the amplitude and frequency of sIPSC were not affected by ILTG. Therefore, our results suggest a potential role of ILTG as a modulator of GABAergic synaptic transmission.
Adult mice (7~9 weeks) were deeply anaesthetized until cessation of breathing and subsequently decapitated. The brain was rapidly removed and submerged in an ice-cold oxygenated artificial cerebrospinal fluid (ACSF) composed of (in mM) 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 1 CaCl2, 3 MgCl2, 10 glucose at pH 7.4, and was bubbled with 5% CO2 / 95% O2. Transverse mouse brain slices (350~400 µm) containing hippocampus were acutely prepared with a Leica vibratome (Leica VT1000S), and incubated in a chamber with oxygenated ACSF at room temperature for 1 hr before use.
The standard ACSF recording solution was composed of (mM): 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 1.5 CaCl2, 1.5 MgCl2 and 10 glucose saturated with 95% O2~5% CO2, at pH 7.4. The internal solution was composed of (mM): 140 CsCl, 10 EGTA, 10 HEPES, 4 Mg-ATP, 2 QX-314. To block the spontaneous EPSC, APV (50 µM; Tocris) and CNQX (20 µM; Tocris) were added into ACSF. Recordings were obtained using Axopatch 200A (Axon instruments, Union City, CA, USA) and filtered at 2 kHz. In case of sIPSC recording, recordings were digitized at 10 kHz, and analyzed using pCLAMP 9 (Molecular devices) and Mini Analysis Program (Synaptosoft) as previously described . The sEPSCs were automatically detected and grouped as fast (1~5 ms) and slow rise time (5~10 ms). All experimental procedures described were performed in accordance with the institutional guidelines of Korea Institute of Science and Technology (KIST, Seoul, Korea).
Statistical comparisons were performed using independent t-tests for two groups and one-way ANOVA test for three groups. Data were expressed as the mean±S.E.M. Differences were considered significant at **p<0.01.
To examine the role of ILTG in the inhibitory synaptic response, we performed the whole-cell patch clamp in hippocampal CA1 pyramidal neurons (Fig. 1A) and measured the sIPSCs at -60mV in the presence of APV and CNQX to block the EPSCs (Fig. 1B). However, the amplitude and frequency of sIPSC were not changed before and after treatment of ILTG (1 µM) by bath application (Fig. 1C~E). This indicates that ILTG does not affect the presynaptic release of GABA and postsynaptic receptor number.
Although ILTG had little effect on sIPSC amplitude and frequency, we analyzed the sIPSC in more detail by measuring the decay tau value after single-exponential decay fitting. Interestingly, ILTG significantly increased the decay time (Fig. 2 control: 18.3±1.9 ms; ILTG: 23.5±2.1 ms). In a recent study, it has been reported that ILTG enhanced the GABA-induced current in dorsal raphe neurons by modulating GABAAR . To test this, we applied flumazenil (FLU, 5 µM), a specific GABAAR antagonist, into ILTG-treated slice. The enhancement of decay time of sIPSC by ILTG was fully restored to control (Fig. 2B, control: 18.3±1.9 ms; ILTG: 23.5±2.1 ms; ILTG+FLU: 19.1±1.7 ms).
We have reported that ILTG functions as a positive allosteric modulator of GABAA-BZP receptor . To confirm this, we measured the decay time of sIPSC using well known modulator for GABAA-BZP receptor, diazepam (DZP, 1 µM). Just as ILTG, DZP significantly enhanced the decay time of sIPSC (Fig. 3A and B, control: 19.2±1.3 ms; ILTG: 24.9±2.1.6 ms), but did not affect the amplitude and frequency of sIPSC (Fig. 3C and D). These results suggest that ILTG prolonged the sIPSC decay effectively by modulating the GABAA-BZP receptor via a mechanism similar to that of DZP.
Here we reported that ILTG significantly enhanced the decay time of sIPSC but had little effect on sIPSC amplitude and frequency. These results is consistent with other modulator for GABAA-BZP receptor, flunitrazepam  and DZP (Fig. 3). These results suggest that a similar number of GABA channels are activated initially during the brief synaptic release of GABA generating IPSC. However, the channel opening frequency is increased by modulators for GABAA-BZP receptor producing longer decays after channel activation [14, 15]. In a previous study, we showed that ILTG enhanced the GABA-induced current in a dose-dependent manner in dorsal raphe neurons . The enhancement was 266% by DZP and 151% by ILTG at 1 µM concentration. We prediced that ILTG can enhance the decay time of sIPSCs in a concentration dependent manner, however, in the present study we used 1 µM ILTG to obtain maximal enhancement. Contrary to the GABA-induced current, the enhancement of sIPSC decay time was similar between DZP and ILTG at 1 µM concentration.
GABAARs activity can be modulated by various drugs including benzodiazepines, barbiturates, ethanol, neurosteroids, anesthetics, and ionic zinc with separate binding sites [16, 17, 18]. This modulation was measured in various brain regions such as thalamus, hippocampus, suprachiasmatic nucleus [13, 19, 20] and had many critical role in brain activity not only in physiological condition but in pathophysiological condition including various diseases such as depression, seizure, schizophrenia, and etc [21, 22, 23].
Here we have investigated that ILTG modulates the sIPSC by enhancing response time as a positive allosteric modulator of GABAA-BZP receptor in hippocampal CA1 pyramidal neurons. It has been reported that ILTG inhibits the mitogen-activated protein kinase (MAPK) pathway and chronic benzodiazepine administration reduced the NMDAR activation in hippocampus [8, 19]. Both MAPK pathway and NMDAR are critically involved in hippocampal synaptic plasticity and spatial memory [24, 25, 26, 27]. We can postulate that ILTG could be a negative regulator for NMDAR-dependent synaptic plasticity and relating behavior, which has not been studied yet. Future studies are needed to study the function of ILTG in hippocampal brain function such as synaptic plasticity and memory.
DZP is widely used to treat various diseases including anxiety, seizures and insomnia by modulating GABAA Rs through the binding to the GABAA-BZP receptor. However, DZP has some adverse effects including anterograde amnesia, sedation and depression [28, 29, 30]. ILTG shows hypnotic effects, having 65 fold higher binding affinity than that of DZP , suggesting that ILTG could be a potential drug for the treatment of sleep as a natural compound from flavonoids. Therefore, this study suggests that ILTG is a potential drug to treat various diseases of sleep and seizures related to GABAergic synaptic transmission.